A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T76810 | Ganitumab | 905703-97-1 | 98% |
Ganitumab
|
Ganitumab (AMG 479) is a highly potent monoclonal antibody to type 1 insulin-like growth factor receptor (IGF1R). Ganitumab is recognized to bind to IGF1R at low... | ||||
T76815 | Lexatumumab | 845816-02-6 | 98% |
Lexatumumab
|
Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant meso... | ||||
T76828 | Sonepcizumab | 1031360-18-5 | 98% |
Sonepcizumab
|
Sonepcizumab (LT 1009) is a fully humanized monoclonal antibody against S1P. Sonepcizumab has anti-cancer activity and can be used to study metastatic renal cell... | ||||
T76831 | Tesidolumab | 1531594-08-7 | 98% |
Tesidolumab
|
Tesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody. Tesidolumab (LFG316) has an inhibitory effect on crovalimab and C5, blocking the cuttin... | ||||
T76844 | Abciximab | 143653-53-6 | 98% |
Abciximab
|
Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leuk... | ||||
T76856 | Andecaliximab | 1518996-49-0 | 98% |
Andecaliximab
|
Andecaliximab is a recombinant IgG4 monoclonal antibody targeting matrix metalloproteinase 9 (MMP9). Andecaliximab showed antifibrotic effects in a mouse model o... | ||||
T76857 | Anetumab | 1954758-84-9 | 98% |
|
Anetumab is a novel fully human anti-mesothelin IgG1 antibody that is a naked antibody to Anetumab ravtansine.Anetumab can be used to synthesize the antibody-act... | ||||
T76858 | Ascrinvacumab | 1463459-96-2 | 98% |
Ascrinvacumab
|
Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1. Ascrinvacumab has a Kd value of 7 nM for human ALK1. Ascrinvacumab has ... | ||||
T76861 | Cinpanemab | 2094516-02-4 | 98% |
Cinpanemab
|
Cinpanemab (BIIB054) is a novel human monoclonal antibody with affinity for alpha-synuclein residues 1-10. Cinpanemab can be used to study Parkinson's disease an... | ||||
T76863 | Elezanumab | 1791416-49-3 | 98% |
|
Elezanumab(ABT-555) is a potent human anti-RGMa monoclonal antibody.Elezanumab exerts its inhibitory effect on RGMa-mediated BMP signaling through the SMAD1/5/8 ... | ||||
T76864 | Enapotamab | 1912423-61-0 | 98% |
Enapotamab
|
Enapotamab is an AXL/UFO-related antibody that can be used to synthesize antibody-drug couplings (Enapotamab Vedotin). | ||||
T76866 | Icrucumab | 1024603-92-6 | 98% |
|
Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.Icrucumab has antitumor activity.Icrucumab ... | ||||
T76867 | Ravulizumab | 1803171-55-2 | 98% |
Ravulizumab
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody targeting complement factor 5 that specifically binds to human complement protein C5 with high affinity... | ||||
T76870 | Narsoplimab | 2108782-45-0 | 98% |
Narsoplimab
|
Narsoplimab (OMS 721) is a selective whole-human immunoglobulin gamma-4 (IgG4) monoclonal antibody, a mannan-binding lectin-associated serine protease-2 (MASP-2)... | ||||
T76873 | Nidanilimab | 2171061-85-9 | 98% |
Nidanilimab
|
Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. Nidanilimab has antitumor activity, cutting off the IL1α and IL1β... | ||||
T76874 | Erenumab | 1582205-90-0 | 98% |
Erenumab
|
Erenumab is a whole-human monoclonal antibody. Erenumab inhibits calcitonin gene-related peptide (CGRP) receptors. Erenumab can be used to prevent migraine attac... | ||||
T76877 | Vofatamab | 1312305-12-6 | 98% |
|
Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combinatio... | ||||
T76882 | Talquetamab | 2226212-40-2 | 98% |
|
Talquetamab (JNJ-64407564) is a T-cell retargeting GPRC5D bispecific antibody for multiple myeloma with antitumor activity that induces T-cell-mediated killing o... | ||||
T76883 | Talacotuzumab | 1826831-79-1 | 98% |
Talacotuzumab
|
Talacotuzumab (JNJ 56022473) is an IgG1 fully humanized CD123 neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has a high affin... | ||||
T76884 | Spesolimab | 2097104-58-8 | 98% |
Spesolimab
|
Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. IL-36 plays an important role in the immune system and is associated with a reduction in biom... |